166 related articles for article (PubMed ID: 21286343)
1. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.
Pattullo V; Heathcote EJ; Wong DK
Hepatol Int; 2010 Aug; 4(4):723-31. PubMed ID: 21286343
[TBL] [Abstract][Full Text] [Related]
2. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.
Vutien P; Nguyen NH; Trinh HN; Li J; Garcia RT; Garcia G; Nguyen KK; Nguyen HA; Levitt BS; Keeffe EB; Nguyen MH
Am J Gastroenterol; 2010 May; 105(5):1110-5. PubMed ID: 19904247
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
5. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
6. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
Missiha S; Heathcote J; Arenovich T; Khan K;
Am J Gastroenterol; 2007 Oct; 102(10):2181-8. PubMed ID: 17640318
[TBL] [Abstract][Full Text] [Related]
7. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
Hsu CS; Liu CH; Liu CJ; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2009; 14(1):45-54. PubMed ID: 19320236
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
11. Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
Yan KK; Guirgis M; Dinh T; George J; Dev A; Lee A; Zekry A
World J Gastroenterol; 2008 Jun; 14(21):3416-20. PubMed ID: 18528940
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.
Chu CJ; Lee SD; Hung TH; Lin HC; Hwang SJ; Lee FY; Lu RH; Yu MI; Chang CY; Yang PL; Lee CY; Chang FY
Aliment Pharmacol Ther; 2009 Jan; 29(1):46-54. PubMed ID: 18680550
[TBL] [Abstract][Full Text] [Related]
13. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
Srivastava S; Bertagnolli M; Lewis JH
J Natl Med Assoc; 2005 Dec; 97(12):1703-7. PubMed ID: 16396063
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
15. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
[TBL] [Abstract][Full Text] [Related]
16. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
17. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
[TBL] [Abstract][Full Text] [Related]
18. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.
Dogan UB; Akin MS; Yalaki S
World J Gastroenterol; 2013 Dec; 19(46):8678-86. PubMed ID: 24379586
[TBL] [Abstract][Full Text] [Related]
19. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
[TBL] [Abstract][Full Text] [Related]
20. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
